---
document_datetime: 2025-12-02 04:49:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zepatier.html
document_name: zepatier.html
version: success
processing_time: 0.116305
conversion_datetime: 2025-12-26 12:02:22.663784
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zepatier

[RSS](/en/individual-human-medicine.xml/66740)

##### Authorised

This medicine is authorised for use in the European Union

elbasvir / grazoprevir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zepatier](#news-on)
- [More information on Zepatier](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Zepatier. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zepatier.

For practical information about using Zepatier, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Zepatier and what is it used for?

Zepatier is an antiviral medicine used to treat adults and children from 12 years of age weighing at least 30 kg with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus.

Zepatier contains the active substances elbasvir and grazoprevir.

## How is Zepatier used?

Zepatier can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C.

There are several varieties (called genotypes) of hepatitis C virus. Zepatier is recommended for use in patients infected with hepatitis C virus genotypes 1a, 1b and 4 who may or may not have compensated liver cirrhosis (scarring of the liver but the liver is still able to work adequately).

Zepatier is available as tablets. The usual dose is 50 mg elbasvir and 100 mg grazoprevir taken once a day for 12 weeks. In some cases, treatment may be longer and Zepatier may be used together with another medicine called ribavirin.

For more information about using Zepatier, see the package leaflet or contact your doctor or pharmacist.

## How does Zepatier work?

The active substances in Zepatier, elbasvir and grazoprevir, block two proteins essential for the hepatitis C virus to multiply. Elbasvir blocks the action of a protein called 'NS5A', while grazoprevir blocks an enzyme called 'NS3/4A protease'. By blocking these proteins, Zepatier stops the hepatitis C virus from multiplying and infecting new cells.

## What benefits of Zepatier have been shown in studies?

Zepatier with or without ribavirin has been investigated in eight main studies involving around 2,000 adults infected with hepatitis C virus of various genotypes whose liver was working normally or adequately. In all studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment. Looking at the results of the studies together, 96% of patients with genotype 1b virus (301 out of 312 patients) tested negative for the virus after 12 weeks of treatment with Zepatier. For patients with genotype 1a virus, 93% of patients (483 out of 519 patients) treated with Zepatier tested negative compared with 95% (55 out of 58 patients) on Zepatier with ribavirin. For patients with genotype 4 virus, 94% of patients (61 out of 65 patients) treated with Zepatier tested negative compared with 100% (8 out of 8 patients) treated with Zepatier and ribavirin. Benefit was also seen in patients also infected with HIV or who had chronic (long-term) kidney disease. The available data in patients with genotype 3 virus were not sufficient to support the use of Zepatier for this genotype.A study conducted in 22 patients older than 12 and younger than 18 years of age showed that the way Zepatier is absorbed, processed and removed from the body in this age group and in adults is similar. Zepatier is therefore expected to show similar safety and effectiveness. In addition, in this study all 22 patients tested negative for the virus after 12 weeks of treatment.

## What are the risks associated with Zepatier?

The most common side effects with Zepatier (which may affect more than 1 in 10 people) are tiredness and headache. For the full list of all side effects reported with Zepatier, see the package leaflet.

Zepatier must not be used in patients with moderately or severely reduced liver function (Child-Pugh class B or C cirrhosis). It must not be used together with medicines such as the antibiotic rifampicin, certain HIV medicines and ciclosporin (used to prevent organ rejection) since Zepatier may affect the way these medicine work. It must also not be used with the herbal remedy St. John's wort (used for depression and anxiety), or the epilepsy medicines carbamazepine and phenytoin because these medicines may affect the way Zepatier works. For the full list of restrictions, see the package leaflet.

## Why is Zepatier approved?

Zepatier has been shown to be highly effective in clearing the hepatitis C virus genotypes 1a, 1b and 4 from the blood of patients with or without compensated cirrhosis, including patients also infected with HIV or who have chronic kidney disease. In most of the studies, treatment with Zepatier was not compared with another treatment or no treatment. This was considered acceptable because chronic hepatitis C virus is very rarely cured without treatment and, at the time the studies started, other antiviral medications such as Zepatier were not available. Zepatier was well tolerated with a favourable safety profile.

The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zepatier's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zepatier?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zepatier have been included in the summary of product characteristics and the package leaflet.

## Other information about Zepatier

The European Commission granted a marketing authorisation valid throughout the European Union for Zepatier on 22 July 2016.

. For more information about treatment with Zepatier, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Zepatier : EPAR - Summary for the public

Reference Number: EMA/572956/2021

English (EN) (119.14 KB - PDF)

**First published:** 28/07/2016

**Last updated:** 09/02/2022

[View](/en/documents/overview/zepatier-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-746)

български (BG) (144.05 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/bg/documents/overview/zepatier-epar-summary-public_bg.pdf)

español (ES) (118.81 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/es/documents/overview/zepatier-epar-summary-public_es.pdf)

čeština (CS) (141.8 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/cs/documents/overview/zepatier-epar-summary-public_cs.pdf)

dansk (DA) (117.05 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/da/documents/overview/zepatier-epar-summary-public_da.pdf)

Deutsch (DE) (121.56 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/de/documents/overview/zepatier-epar-summary-public_de.pdf)

eesti keel (ET) (104.82 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/et/documents/overview/zepatier-epar-summary-public_et.pdf)

ελληνικά (EL) (148.31 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/el/documents/overview/zepatier-epar-summary-public_el.pdf)

français (FR) (119.58 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/fr/documents/overview/zepatier-epar-summary-public_fr.pdf)

hrvatski (HR) (159.44 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/hr/documents/overview/zepatier-epar-summary-public_hr.pdf)

italiano (IT) (115.47 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/it/documents/overview/zepatier-epar-summary-public_it.pdf)

latviešu valoda (LV) (173.1 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/lv/documents/overview/zepatier-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (139.08 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/lt/documents/overview/zepatier-epar-summary-public_lt.pdf)

magyar (HU) (139.46 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/hu/documents/overview/zepatier-epar-summary-public_hu.pdf)

Malti (MT) (152.49 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/mt/documents/overview/zepatier-epar-summary-public_mt.pdf)

Nederlands (NL) (117.52 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/nl/documents/overview/zepatier-epar-summary-public_nl.pdf)

polski (PL) (142.75 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/pl/documents/overview/zepatier-epar-summary-public_pl.pdf)

português (PT) (109.55 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/pt/documents/overview/zepatier-epar-summary-public_pt.pdf)

română (RO) (136.63 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/ro/documents/overview/zepatier-epar-summary-public_ro.pdf)

slovenčina (SK) (140.7 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/sk/documents/overview/zepatier-epar-summary-public_sk.pdf)

slovenščina (SL) (137.2 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/sl/documents/overview/zepatier-epar-summary-public_sl.pdf)

Suomi (FI) (134.45 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/fi/documents/overview/zepatier-epar-summary-public_fi.pdf)

svenska (SV) (114.78 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

09/02/2022

[View](/sv/documents/overview/zepatier-epar-summary-public_sv.pdf)

Zepatier : EPAR - Risk management plan summary

English (EN) (138.54 KB - PDF)

**First published:** 09/02/2022

[View](/en/documents/rmp-summary/zepatier-epar-risk-management-plan-summary_en.pdf)

## Product information

Zepatier : EPAR - Product information

English (EN) (440.24 KB - PDF)

**First published:** 28/07/2016

**Last updated:** 07/11/2025

[View](/en/documents/product-information/zepatier-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-932)

български (BG) (416.66 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/bg/documents/product-information/zepatier-epar-product-information_bg.pdf)

español (ES) (474.88 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/es/documents/product-information/zepatier-epar-product-information_es.pdf)

čeština (CS) (480.42 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/cs/documents/product-information/zepatier-epar-product-information_cs.pdf)

dansk (DA) (467.13 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/da/documents/product-information/zepatier-epar-product-information_da.pdf)

Deutsch (DE) (496.09 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/de/documents/product-information/zepatier-epar-product-information_de.pdf)

eesti keel (ET) (450.32 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/et/documents/product-information/zepatier-epar-product-information_et.pdf)

ελληνικά (EL) (446.24 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/el/documents/product-information/zepatier-epar-product-information_el.pdf)

français (FR) (531.05 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/fr/documents/product-information/zepatier-epar-product-information_fr.pdf)

hrvatski (HR) (479.07 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/hr/documents/product-information/zepatier-epar-product-information_hr.pdf)

íslenska (IS) (448.25 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/is/documents/product-information/zepatier-epar-product-information_is.pdf)

italiano (IT) (485.22 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/it/documents/product-information/zepatier-epar-product-information_it.pdf)

latviešu valoda (LV) (432.66 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/lv/documents/product-information/zepatier-epar-product-information_lv.pdf)

lietuvių kalba (LT) (460.84 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/lt/documents/product-information/zepatier-epar-product-information_lt.pdf)

magyar (HU) (521.7 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/hu/documents/product-information/zepatier-epar-product-information_hu.pdf)

Malti (MT) (502.41 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/mt/documents/product-information/zepatier-epar-product-information_mt.pdf)

Nederlands (NL) (461.74 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/nl/documents/product-information/zepatier-epar-product-information_nl.pdf)

norsk (NO) (445.23 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/no/documents/product-information/zepatier-epar-product-information_no.pdf)

polski (PL) (525.84 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/pl/documents/product-information/zepatier-epar-product-information_pl.pdf)

português (PT) (463.09 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/pt/documents/product-information/zepatier-epar-product-information_pt.pdf)

română (RO) (471.98 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/ro/documents/product-information/zepatier-epar-product-information_ro.pdf)

slovenčina (SK) (492.02 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/sk/documents/product-information/zepatier-epar-product-information_sk.pdf)

slovenščina (SL) (463.38 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/sl/documents/product-information/zepatier-epar-product-information_sl.pdf)

Suomi (FI) (472.48 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/fi/documents/product-information/zepatier-epar-product-information_fi.pdf)

svenska (SV) (451.22 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

07/11/2025

[View](/sv/documents/product-information/zepatier-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000310229 07/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zepatier : EPAR - All Authorised presentations

English (EN) (55.67 KB - PDF)

**First published:** 28/07/2016

**Last updated:** 28/07/2016

[View](/en/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-502)

български (BG) (58.12 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/bg/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_bg.pdf)

español (ES) (55.39 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/es/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.73 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/cs/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.11 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/da/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (68.01 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/de/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.94 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/et/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (58.47 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/el/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_el.pdf)

français (FR) (55.01 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/fr/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (55.69 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/hr/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (55.84 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/is/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.13 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/it/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.95 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/lv/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.11 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/lt/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.18 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/hu/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.88 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/mt/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.47 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/nl/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (55.97 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/no/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_no.pdf)

polski (PL) (56.58 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/pl/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_pl.pdf)

português (PT) (55.89 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/pt/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_pt.pdf)

română (RO) (26.78 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/ro/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.27 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/sk/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.3 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/sl/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.29 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/fi/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (55.39 KB - PDF)

**First published:**

28/07/2016

**Last updated:**

28/07/2016

[View](/sv/documents/all-authorised-presentations/zepatier-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zepatier Active substance

- elbasvir
- grazoprevir

International non-proprietary name (INN) or common name

- elbasvir
- grazoprevir

Therapeutic area (MeSH) Hepatitis C, Chronic Anatomical therapeutic chemical (ATC) code J05AP54

### Pharmacotherapeutic group

- Direct acting antivirals
- Antivirals for systemic use
- Antivirals for treatment of HCV infections

### Therapeutic indication

ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).

For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.

## Authorisation details

EMA product number EMEA/H/C/004126 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 26/05/2016 Marketing authorisation issued 22/07/2016 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zepatier : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (203.72 KB - PDF)

**First published:** 07/05/2025

**Last updated:** 07/11/2025

[View](/en/documents/procedural-steps-after/zepatier-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zepatier : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (140.83 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 07/05/2025

[View](/en/documents/procedural-steps-after/zepatier-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zepatier : EPAR - Scientific conclusions - Annex IV

English (EN) (132.26 KB - PDF)

**First published:** 07/07/2022

[View](/en/documents/scientific-conclusion/zepatier-epar-scientific-conclusions-annex-iv_en.pdf)

Zepatier-H-C-004126-II-0029 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/564993/2021

English (EN) (1.79 MB - PDF)

**First published:** 09/02/2022

[View](/en/documents/variation-report/zepatier-h-c-004126-ii-0029-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Zepatier (II-29)

Adopted

Reference Number: EMA/CHMP/505022/2021

English (EN) (127.43 KB - PDF)

**First published:** 17/09/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-zepatier-ii-29_en.pdf)

## Initial marketing authorisation documents

Zepatier : EPAR - Public assessment report

Adopted

Reference Number: EMA/419807/2016

English (EN) (4.86 MB - PDF)

**First published:** 28/07/2016

**Last updated:** 28/07/2016

[View](/en/documents/assessment-report/zepatier-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Zepatier

Adopted

Reference Number: EMA/CHMP/342247/2016

English (EN) (61.77 KB - PDF)

**First published:** 27/05/2016

**Last updated:** 27/05/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-zepatier_en.pdf)

#### News on Zepatier

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021) 17/09/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-may-2016) 27/05/2016

[Two new combination therapies against chronic hepatitis C](/en/news/two-new-combination-therapies-against-chronic-hepatitis-c) 27/05/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0041260000) (initial marketing authorisation)

#### More information on Zepatier

- [EMEA-001604-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001604-pip01-13-m03)
- [A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS) - post-authorisation study](https://catalogues.ema.europa.eu/study/44706)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/11/2025

## Share this page

[Back to top](#main-content)